= Discovery stage. (16.60%, 2024)
= Translation stage. (37.02%, 2024)
= Clinically available. (46.38%, 2024)
MSACL 2024 : Session
MSACL 2024 Abstract
Self-Classified Topic Area(s):
Small Molecule
> none > none
Podium Presentation
in Steinbeck 1 on Thursday at 16:00
(Chair: Briana Fitch)
Discussion on Impending FDA Regulation of Clinical Lab LDTs
Discussion Session
(Presenter)
Abstract
Panel Discussion with Stephen Master, Andy Hoofnagle, Gwen McMillan, Dennis Dietzen and Kara Lynch.
Financial Disclosure
Description
Y/N
Source
Grants
no
Salary
no
Board Member
no
Stock
no
Expenses
no
IP Royalty
no
Planning to mention or discuss specific products or technology of the company(ies) listed above:
no
= Discovery stage. (16.60%, 2024)
= Translation stage. (37.02%, 2024)
= Clinically available. (46.38%, 2024)
